$AQST I like the hype of all the YouTube videos on AQST but damn those people don't know how to make a proper DD! They all talk about the fda run-up with Libervant, chart and price target but no one is talking about AQST-108 and especially AQST-109. Those are blockbuster potential who can revolutionize the Epinephrine autoinjector (Epipen) monopoly with a better way to transport (can fit in a pocket) and administrate the product (orally). That's a major catalyst (clinical result) that can come anytime from today until December 31 ("second half of 21"). This is not like a pump and dump play only for the FDA run-up for Libervant December 23 guys! That's also why price target is so high for many analysts.
9
3
3 Likes